Pulmonary monoclonal antibody delivery via a portable microfluidic nebulization platform

Christina Cortez-Jugo, Aisha Qi, Anushi Rajapaksa, James R Friend, Leslie Y Yeo

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Nebulizers have considerable advantages over conventional inhalers for pulmonary drug administration, particularly because they do not require coordinated breath actuation to generate and deliver the aerosols. Nevertheless, besides being less amenable to miniaturization and hence portability, some nebulizers are prone to denature macromolecular drugs due to the large forces generated during aerosolization. Here, we demonstrate a novel portable acoustomicrofluidic device capable of nebulizing epidermal growth factor receptor (EGFR) monoclonal antibodies into a fine aerosol mist with a mass median aerodynamic diameter of approximately 1.1 μm, optimal for deep lung deposition via inhalation. The nebulized monoclonal antibodies were tested for their stability, immunoactivity, and pharmacological properties, which confirmed that nebulization did not cause significant degradation of the antibody. In particular, flow cytometry demonstrated that the antigen binding capability of the antibody is retained and able to reduce phosphorylation in cells overexpressing the EGFR, indicating that the aerosols generated by the device were loaded with stable and active monoclonal antibodies. The delivery of antibodies via inhalation, particularly for the treatment of lung cancer, is thus expected to enhance the efficacy of this protein therapeutic by increasing the local concentration where they are needed.
Original languageEnglish
Article number052603
Pages (from-to)1-10
Number of pages10
JournalBiomicrofluidics
Volume9
Issue number5
DOIs
Publication statusPublished - 2015

Cite this

Cortez-Jugo, C., Qi, A., Rajapaksa, A., Friend, J. R., & Yeo, L. Y. (2015). Pulmonary monoclonal antibody delivery via a portable microfluidic nebulization platform. Biomicrofluidics, 9(5), 1-10. [052603]. https://doi.org/10.1063/1.4917181
Cortez-Jugo, Christina ; Qi, Aisha ; Rajapaksa, Anushi ; Friend, James R ; Yeo, Leslie Y. / Pulmonary monoclonal antibody delivery via a portable microfluidic nebulization platform. In: Biomicrofluidics. 2015 ; Vol. 9, No. 5. pp. 1-10.
@article{aeb13ddb2e6b4878a3cc6e59e11b9da4,
title = "Pulmonary monoclonal antibody delivery via a portable microfluidic nebulization platform",
abstract = "Nebulizers have considerable advantages over conventional inhalers for pulmonary drug administration, particularly because they do not require coordinated breath actuation to generate and deliver the aerosols. Nevertheless, besides being less amenable to miniaturization and hence portability, some nebulizers are prone to denature macromolecular drugs due to the large forces generated during aerosolization. Here, we demonstrate a novel portable acoustomicrofluidic device capable of nebulizing epidermal growth factor receptor (EGFR) monoclonal antibodies into a fine aerosol mist with a mass median aerodynamic diameter of approximately 1.1 μm, optimal for deep lung deposition via inhalation. The nebulized monoclonal antibodies were tested for their stability, immunoactivity, and pharmacological properties, which confirmed that nebulization did not cause significant degradation of the antibody. In particular, flow cytometry demonstrated that the antigen binding capability of the antibody is retained and able to reduce phosphorylation in cells overexpressing the EGFR, indicating that the aerosols generated by the device were loaded with stable and active monoclonal antibodies. The delivery of antibodies via inhalation, particularly for the treatment of lung cancer, is thus expected to enhance the efficacy of this protein therapeutic by increasing the local concentration where they are needed.",
author = "Christina Cortez-Jugo and Aisha Qi and Anushi Rajapaksa and Friend, {James R} and Yeo, {Leslie Y}",
year = "2015",
doi = "10.1063/1.4917181",
language = "English",
volume = "9",
pages = "1--10",
journal = "Biomicrofluidics",
issn = "1932-1058",
publisher = "AIP Publishing",
number = "5",

}

Cortez-Jugo, C, Qi, A, Rajapaksa, A, Friend, JR & Yeo, LY 2015, 'Pulmonary monoclonal antibody delivery via a portable microfluidic nebulization platform' Biomicrofluidics, vol. 9, no. 5, 052603, pp. 1-10. https://doi.org/10.1063/1.4917181

Pulmonary monoclonal antibody delivery via a portable microfluidic nebulization platform. / Cortez-Jugo, Christina; Qi, Aisha; Rajapaksa, Anushi; Friend, James R; Yeo, Leslie Y.

In: Biomicrofluidics, Vol. 9, No. 5, 052603, 2015, p. 1-10.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Pulmonary monoclonal antibody delivery via a portable microfluidic nebulization platform

AU - Cortez-Jugo, Christina

AU - Qi, Aisha

AU - Rajapaksa, Anushi

AU - Friend, James R

AU - Yeo, Leslie Y

PY - 2015

Y1 - 2015

N2 - Nebulizers have considerable advantages over conventional inhalers for pulmonary drug administration, particularly because they do not require coordinated breath actuation to generate and deliver the aerosols. Nevertheless, besides being less amenable to miniaturization and hence portability, some nebulizers are prone to denature macromolecular drugs due to the large forces generated during aerosolization. Here, we demonstrate a novel portable acoustomicrofluidic device capable of nebulizing epidermal growth factor receptor (EGFR) monoclonal antibodies into a fine aerosol mist with a mass median aerodynamic diameter of approximately 1.1 μm, optimal for deep lung deposition via inhalation. The nebulized monoclonal antibodies were tested for their stability, immunoactivity, and pharmacological properties, which confirmed that nebulization did not cause significant degradation of the antibody. In particular, flow cytometry demonstrated that the antigen binding capability of the antibody is retained and able to reduce phosphorylation in cells overexpressing the EGFR, indicating that the aerosols generated by the device were loaded with stable and active monoclonal antibodies. The delivery of antibodies via inhalation, particularly for the treatment of lung cancer, is thus expected to enhance the efficacy of this protein therapeutic by increasing the local concentration where they are needed.

AB - Nebulizers have considerable advantages over conventional inhalers for pulmonary drug administration, particularly because they do not require coordinated breath actuation to generate and deliver the aerosols. Nevertheless, besides being less amenable to miniaturization and hence portability, some nebulizers are prone to denature macromolecular drugs due to the large forces generated during aerosolization. Here, we demonstrate a novel portable acoustomicrofluidic device capable of nebulizing epidermal growth factor receptor (EGFR) monoclonal antibodies into a fine aerosol mist with a mass median aerodynamic diameter of approximately 1.1 μm, optimal for deep lung deposition via inhalation. The nebulized monoclonal antibodies were tested for their stability, immunoactivity, and pharmacological properties, which confirmed that nebulization did not cause significant degradation of the antibody. In particular, flow cytometry demonstrated that the antigen binding capability of the antibody is retained and able to reduce phosphorylation in cells overexpressing the EGFR, indicating that the aerosols generated by the device were loaded with stable and active monoclonal antibodies. The delivery of antibodies via inhalation, particularly for the treatment of lung cancer, is thus expected to enhance the efficacy of this protein therapeutic by increasing the local concentration where they are needed.

UR - http://scitation.aip.org/content/aip/journal/bmf/9/5/10.1063/1.4917181

U2 - 10.1063/1.4917181

DO - 10.1063/1.4917181

M3 - Article

VL - 9

SP - 1

EP - 10

JO - Biomicrofluidics

JF - Biomicrofluidics

SN - 1932-1058

IS - 5

M1 - 052603

ER -